Digital support for type 2 diabetes patients remain limited

This presents opportunities for digital marketing of T2D therapeutics.

Although the Japanese type 2 diabetes (T2D) therapeutics market is highly competitive with several generic, branded and biosimilar products available, the digital support available for such patients is limited, according to a report from GlobalData.

The market size of T2D in Japan is projected to grow from $3.3b in 2020 to $5.1b in 2028 at a compound annual growth rate of 5.4%.

“The T2D treatment landscape in Japan is mature with several medications available for patients. However, the digital marketing space has not evolved in line with the available therapies and does not offer comprehensive digital offerings to patients,” GlobalData’s pharma analyst Venkat Kartheek Vale said.

The digital marketing space for T2D therapeutics in the country can provide current and future players in the market with opportunities to expand their digital presence and raise awareness about their brands.

GlobalData noted that the lack of branded support from most of the leading players offers opportunities to design effective branded digital strategies and allows market players to maintain a continuous relationship with patients and to ensure effective management of their condition.

“T2D is a disease with increasing prevalence, progressive nature and considerably high unmet needs, thus demanding the right treatment information and treatment support for better disease management,” Vale added.